Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

8.870 -0.360 (-3.90%)
Streaming Delayed Price Updated: 1:59 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts ↗
 
Via Benzinga
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts ↗
 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Expectations For 4D Molecular Therapeutics's Future ↗
 
Via Benzinga
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study ↗
4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements. 
Via Benzinga
News headline image
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings For 4D Molecular Therapeutics ↗
 
Via Benzinga
News headline image
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation 
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate ↗
4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to... 
Via Benzinga
News headline image
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
4DMT Announces Presentations at Upcoming Retina Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.